Anne Fiquet

513 total citations
22 papers, 357 citations indexed

About

Anne Fiquet is a scholar working on Epidemiology, Infectious Diseases and Microbiology. According to data from OpenAlex, Anne Fiquet has authored 22 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Epidemiology, 7 papers in Infectious Diseases and 7 papers in Microbiology. Recurrent topics in Anne Fiquet's work include Bacterial Infections and Vaccines (7 papers), Pneumonia and Respiratory Infections (6 papers) and Virology and Viral Diseases (5 papers). Anne Fiquet is often cited by papers focused on Bacterial Infections and Vaccines (7 papers), Pneumonia and Respiratory Infections (6 papers) and Virology and Viral Diseases (5 papers). Anne Fiquet collaborates with scholars based in France, United Kingdom and United States. Anne Fiquet's co-authors include Stéphane Thomas, Patrick O. Richard, Martine Baudin, B. Soubeyrand, Christine Sadorge, Emilio Ledesma, J. Beytout, Sandrine Samson, Pierre Van Damme and Nicole Guiso and has published in prestigious journals such as Blood, Vaccine and Archives of Disease in Childhood.

In The Last Decade

Anne Fiquet

22 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne Fiquet France	11	258	88	86	62	59	22	357
Stéphane Thomas France	13	442 1.7×	128 1.5×	99 1.2×	98 1.6×	80 1.4×	35	547
Zsófia Mészner Hungary	13	275 1.1×	70 0.8×	143 1.7×	61 1.0×	23 0.4×	40	458
Luodan Suo China	13	396 1.5×	27 0.3×	120 1.4×	97 1.6×	28 0.5×	42	481
Tiina Korhonen Finland	7	186 0.7×	35 0.4×	240 2.8×	37 0.6×	32 0.5×	9	391
Martine Douha Belgium	12	412 1.6×	47 0.5×	115 1.3×	100 1.6×	15 0.3×	13	455
Iris Gorfinkel Canada	5	380 1.5×	28 0.3×	58 0.7×	12 0.2×	108 1.8×	9	436
Christine Sadorge France	10	139 0.5×	75 0.9×	91 1.1×	20 0.3×	65 1.1×	15	356
Maurice Raux France	7	154 0.6×	42 0.5×	88 1.0×	45 0.7×	164 2.8×	7	371
BRENDA O. STAEHLE United States	8	336 1.3×	45 0.5×	80 0.9×	116 1.9×	41 0.7×	9	375
Amalia Magaret United States	11	221 0.9×	86 1.0×	117 1.4×	4 0.1×	43 0.7×	22	367

Countries citing papers authored by Anne Fiquet

Since Specialization

Citations

This map shows the geographic impact of Anne Fiquet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Fiquet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Fiquet more than expected).

Fields of papers citing papers by Anne Fiquet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Fiquet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Fiquet. The network helps show where Anne Fiquet may publish in the future.

Co-authorship network of co-authors of Anne Fiquet

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Fiquet. A scholar is included among the top collaborators of Anne Fiquet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Fiquet. Anne Fiquet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guffon, Nathalie, Pratima Chowdary, Elisa Leão Teles, et al.. (2021). Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil. Journal of Inherited Metabolic Disease. 45(2). 340–352. 9 indexed citations

Creech, C. Buddy, Robert W. Frenck, Anne Fiquet, et al.. (2019). Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag). Open Forum Infectious Diseases. 7(1). ofz532–ofz532. 14 indexed citations

Frenck, Robert W., Anne Fiquet, Alejandra Gurtman, et al.. (2016). Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 34(30). 3454–3462. 21 indexed citations

John, Tessa M., Merryn Voysey, Ly‐Mee Yu, et al.. (2015). Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study. Vaccine. 33(36). 4579–4585. 9 indexed citations

Vesikari, Timo, Roland Hardt, H. C. Rümke, et al.. (2013). Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax^®) in individuals aged ≥ 70 years: A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines & Immunotherapeutics. 9(4). 858–864. 28 indexed citations

Gabutti, Giovanni, H. C. Rümke, Lars Rombo, et al.. (2012). Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine Manufactured With Recombinant Human Albumin. The Pediatric Infectious Disease Journal. 31(11). 1166–1172. 7 indexed citations

Vesikari, Timo, Thomas Becker, Vincent Gajdos, et al.. (2012). Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) in infants from 9 months of age. Vaccine. 30(20). 3082–3089. 20 indexed citations

Montalembert, Mariane de, Miguel R. Abboud, Anne Fiquet, et al.. (2012). A 2-Dose Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Given to Children with Sickle Cell Disease Previously Immunized with 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a Phase 3 Study. Blood. 120(21). 3212–3212. 6 indexed citations

Zanetti, Alessandro, Antonino Parlato, Luisa Romanò, et al.. (2012). Challenge with a hepatitis B vaccine in two cohorts of 4–7-year-old children primed with hexavalent vaccines: An open-label, randomised trial in Italy. Vaccine. 30(39). 5770–5775. 28 indexed citations

10.

Fiquet, Anne, et al.. (2011). Immunogenicity and safety of ZOSTAVAX® approaching expiry potency in individuals aged ≥50 years. Human Vaccines. 7(10). 1060–1065. 12 indexed citations

11.

Gajdos, Vincent, B. Soubeyrand, Emmanuel Vidor, et al.. (2011). Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS^®) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio^®) given as a booster dose at 6 years of age. Human Vaccines. 7(5). 549–556. 10 indexed citations

12.

Damme, Pierre Van, Anne Fiquet, Patrick O. Richard, et al.. (2010). Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infectious Diseases. 10(1). 134–134. 60 indexed citations

13.

Gillet, Yves, et al.. (2009). Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Medicine. 7(1). 16–16. 26 indexed citations

14.

Beytout, J., Odile Launay, Nicole Guiso, et al.. (2009). Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: A placebo-controlled trial. Human Vaccines. 5(5). 315–321. 53 indexed citations

15.

Mair, Stuart, et al.. (2009). Immunogenicity and safety of PNEUMOVAX^®II manufactured by a new process in older adults. Human Vaccines. 5(9). 608–613. 3 indexed citations

16.

Kitchin, Nicholas, Jo Southern, Rhonwen Morris, et al.. (2009). Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine. 27(37). 5096–5102. 14 indexed citations

17.

Gajdos, Vincent, et al.. (2009). Safety of a refrigerator-stable varicella vaccine (VARIVAX®) in healthy 12- to 15-month-old children – a randomized, double-blind, cross-over study. Human Vaccines. 5(7). 455–460. 6 indexed citations

18.

Vesikari, Timo, Aino Karvonen, Nicholas Kitchin, et al.. (2008). CO-ADMINISTRATION OF PENTAVALENT ROTAVIRUS VACCINE, ROTATEQ®, WITH MENINGOCOCCAL GROUP C CONJUGATE VACCINE: IMMUNOGENICITY AND SAFETY. Archives of Disease in Childhood. 93. 1 indexed citations

19.

Stojanov, S, Johannes G. Liese, B. H. Belohradsky, et al.. (2007). Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP–IPV–PRP∼T–HBs) combination vaccine. Vaccine. 25(43). 7549–7558. 10 indexed citations

20.

Reinert, Philippe, et al.. (2006). Fever as a Marker of Reactogenicity of an Acellular Pertussis-Containing Hexavalent Vaccine (HEXAVAC®) in a Large-Scale, Open, Randomized Safety Study in Healthy French Infants. Human Vaccines. 2(5). 215–221. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact